Advanced urothelial carcinoma: Overcoming treatment resistance through novel treatment approaches

Frontiers in Pharmacology

Volumn 4 FEB, Issue , 2013, Pages

  Bambury, Richard M ^a   Rosenberg, Jonathan E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bladder cancer; Chemotherapy; Oncogenes; Resistance mechanisms; Urothelial cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIOXIDANT; AURORA KINASE; BCG VACCINE; BEVACIZUMAB; CARBOPLATIN; CD4 ANTIGEN; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DN 24 02; DRUG EFFLUX PUMP; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEMCITABINE; IPILIMUMAB; MAMMALIAN TARGET OF RAPAMYCIN; MEMBRANE PROTEIN; PACLITAXEL; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; SUNITINIB; TKI 12458; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

ADJUVANT THERAPY; ADVANCED CANCER; APOPTOSIS; BLOOD TOXICITY; BRAF GENE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; DRUG EFFICACY; DRUG TARGETING; ENZYME INACTIVATION; ENZYME INHIBITION; ERBB2 GENE; FGFR3 GENE; GENE; GENE MUTATION; HUMAN; NONHUMAN; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA;

EID: 84881522229     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00003     Document Type: Short Survey

References (74)

1. Bahnson, R. R., Becich, M., Ernstoff, M. S., Sandlow, J., Cohen, M. B., and Williams, R. D. (1994). Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. J. Urol. 152, 2272-2275.
2. Bambury, R. M., and Gallagher, D. J. (2012). Prostate cancer: germline prediction for a commonly variable malignancy. BJU Int.
3. Bamias, A., Dafni, U., Karadimou, A., Timotheadou, E., Aravantinos, G., Psyrri, A., et al. (2012). Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann. Oncol. PMID: 23136231. [Epub ahead of print].
4. Baselga, J., Campone, M., Piccart, M., Burris, H. A. III, Rugo, H. S., Sahmoud, T., et al. (2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520-529.
5. Bellmunt, J., Gonzalez-Larriba, J. L., Prior, C., Maroto, P., Carles, J., Castellano, D., et al. (2011). Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann. Oncol. 22, 2646-2653.
6. Bellmunt, J., Paz-Ares, L., Cuello, M., Cecere, F. L., Albiol, S., Guillem, V., et al. (2007). Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann. Oncol. 18, 522-528.
7. Bellmunt, J., and Petrylak, D. P. (2012). New therapeutic challenges in advanced bladder cancer. Semin. Oncol. 39, 598-607.
8. Bellmunt, J., von der Maase, H., Mead, G. M., Skoneczna, I., De Santis, M., Daugaard, G., et al. (2012). Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J. Clin. Oncol. 30, 1107-1113.
9. Bernardini, S., Fauconnet, S., Chabannes, E., Henry, P. C., Adessi, G., and Bittard, H. (2001). Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J. Urol. 166, 1275-1279.
10. Beuzeboc, P., Banu, E., Voog, E., Bousquet, G., Priou, F., Deplanque, G., et al. (2007). Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: interim safety results of a prospective randomized phase II study. J. Clin. Oncol. 25, 15565.
11. Bochner, B. H., Cote, R. J., Weidner, N., Groshen, S., Chen, S. C., Skinner, D. G., et al. (1995). Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J. Natl. Cancer Inst. 87, 1603-1612.
12. Boulalas, I., Zaravinos, A., Delakas, D., and Spandidos, D. A. (2009). Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder. Int. J. Biol. Markers 24, 17-21.
13. Byun, S. S., Kim, S. W., Choi, H., Lee, C., and Lee, E. (2005). Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU Int. 95, 1086-1090.
14. Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., et al. (2010). Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16, 2861-2871.
15. Chang, J. S., Lara, P. N. Jr., and Pan, C. X. (2012). Progress in personalizing chemotherapy for bladder cancer. Adv. Urol. 2012, 364919.
16. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
17. Ching, C. B., and Hansel, D. E. (2010). Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab. Invest. 90, 1406-1414.
18. Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., et al. (2003). Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431-1439.
19. Cunningham, D., Smith, P., Mouncey, P., Qian, W., Jack, A. S., Pocock, C., et al. (2011). R-CHOP14 versus RCHOP21: result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J. Clin. Oncol. 29 (Suppl.), abstr.:8000.
20. Dietrich, S., Glimm, H., Andrulis, M., Von Kalle, C., Ho, A. D., and Zenz, T. (2012). BRAF inhibition in refractory hairy-cell leukemia. N. Engl. J. Med. 366, 2038-2040.
21. Drayton, R. M., and Catto, J. W. (2012). Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Rev. Anticancer Ther. 12, 271-281.
22. Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
23. Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., Mcarthur, G. A., Sosman, J. A., et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
24. Gallagher, D. J., Joseph, V., Hamilton, R. J., Ostrovnaya, I., Garcia-Grossman, I. R., Riches, J. C., et al. (2011a). Association of germ-line variation with platinum-based chemotherapy response in patients (pts) with urothelial carcinoma (UC). J. Clin. Oncol. 29(Suppl.), 2011, abstr.:4511.
25. Gallagher, D. J., Al-Ahmadie, H., Ostrovnaya, I., Gerst, S. R., Regazzi, A., Garcia-Grossman, I., et al. (2011b). Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response. Eur. Urol. 60, 344-349.
26. Galsky, M. D., Sonpavde, G. S., Hellerstedt, B. A., McKenney, S. A., Hutson, T. E., Rauch, M. A., et al. (2010). Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma (UC). J. Clin. Oncol. 28(Suppl. 15), abstr.:4573.
27. Garg, M., Kanojia, D., Seth, A., Kumar, R., Gupta, A., Surolia, A., et al. (2010). Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. Eur. J. Cancer 46, 207-215.
28. Gautschi, O., Pauli, C., Strobel, K., Hirschmann, A., Printzen, G., Aebi, S., et al. (2012). A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J. Thorac. Oncol. 7, e23-e24.
29. Hadaschik, B. A., Jackson, J., Fazli, L., Zoubeidi, A., Burt, H. M., Gleave, M. E., et al. (2008). Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer. BJU Int. 102, 610-616.
30. Hahn, N. M., Stadler, W. M., Zon, R. T., Waterhouse, D., Picus, J., Nattam, S., et al. (2011). Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J. Clin. Oncol. 29, 1525-1530.
31. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
32. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
33. Hong, J. H., Lee, E., Hong, J., Shin, Y. J., and Ahn, H. (2002). Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. BJU Int. 90, 113-117.
34. Hussain, M. H., MacVicar, G. R., Petrylak, D. P., Dunn, R. L., Vaishampayan, U., Lara, P. N. Jr., et al. (2007). Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J. Clin. Oncol. 25, 2218-2224.
35. Hussain, M. H., Wood, D. P., Bajorin, D. F., Bochner, B. H., Dreicer, R., Lamm, D. L., et al. (2009). Bladder cancer: narrowing the gap between evidence and practice. J. Clin. Oncol. 27, 5680-5684.
36. Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al-Ahmadie, H., Scott, S. N., Janakiraman, M., et al. (2012). Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221.
37. Iyer, G., and Milowsky, M. I. (2012). Fibroblast growth factor receptor-3 in urothelial tumorigenesis. Urol. Oncol. PMID: 22285006. [Epub ahead of print].
38. Janku, F. (2012). "Aberrations in PIK3CA, PTEN, and MAPK (KRAS, NRAS, BRAF) in 1,656 patients and experience with early-phase protocols with PI3K/AKT/mTOR inhibitors," in 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Meeting abstract no. 246.
39. Kamada, M., So, A., Muramaki, M., Rocchi, P., Beraldi, E., and Gleave, M. (2007). Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol. Cancer Ther. 6, 299-308.
40. Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422.
41. Kerr, D. (2012). Is Oncology Ready for 1000 Rare Diseases? Available at: http://www.medscape.com/viewarticle/766796
42. Komatsu, M., Sumizawa, T., Mutoh, M., Chen, Z. S., Terada, K., Furukawa, T., et al. (2000). Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res. 60, 1312-1316.
43. Kompier, L. C., Lurkin, I., van der Aa, M. N., van Rhijn, B. W., dan der Kwast, T. H., and Zwarthoff, E. C. (2010). FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS ONE 5:e13821. doi:10.1371/journal.pone.0013821
44. Kuramitsu, Y., Wang, Y., Taba, K., Suenaga, S., Ryozawa, S., Kaino, S., et al. (2012). Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells. Anticancer Res. 32, 2295-2299.
45. Lae, M., Couturier, J., Oudard, S., Radvanyi, F., Beuzeboc, P., and Vieillefond, A. (2010). Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann. Oncol. 21, 815-819.
46. Miyake, M., Fujimoto, K., Anai, S., Ohnishi, S., Nakai, Y., Inoue, T., et al. (2010). Inhibition of heme oxygenase-1 enhances the cytotoxic effect of gemcitabine in urothelial cancer cells. Anticancer Res. 30, 2145-2152.
47. Morris, P. G., Mcarthur, H. L., Hudis, C., and Norton, L. (2010). Dose-dense chemotherapy for breast cancer: what does the future hold? Future Oncol. 6, 951-965.
48. Morse, M. A., Bradley, D. A., Keler, T., Laliberte, R. J., Green, J. A., Davis, T. A., et al. (2011). CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. Expert Rev. Vaccines 10, 733-742.
49. Muramaki, M., So, A., Hayashi, N., Sowery, R., Miyake, H., Fujisawa, M., et al. (2009). Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. BJU Int. 103, 384-390.
50. Necchi, A., Mariani, L., Zaffaroni, N., Schwartz, L. H., Giannatempo, P., Crippa, F., et al. (2012). Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol. 13, 810-816.
51. Norton, L. (1988). A Gompertzian model of human breast cancer growth. Cancer Res. 48, 7067-7071.
52. O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., et al. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004.
53. Richardson, P. G., Mitsiades, C. S., Laubach, J. P., Lonial, S., Chanan-Khan, A. A., and Anderson, K. C. (2011). Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br. J. Haematol. 152, 367-379.
54. Samimi, G., Safaei, R., Katano, K., Holzer, A. K., Rochdi, M., Tomioka, M., et al. (2004). Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin. Cancer Res. 10, 4661-4669.
55. Seront, E., Rottey, S., Sautois, B., Kerger, J., D'Hondt, L. A., Verschaeve, V., et al. (2012). Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann. Oncol. 23, 2663-2670.
56. Sharma, P., Bajorin, D. F., Jungbluth, A. A., Herr, H., Old, L. J., and Gnjatic, S. (2008). Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J. Immunother. 31, 849-857.
57. Siegel, R., Naishadham, D., and Jemal, A. (2012). Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29.
58. Siegsmund, M. J., Marx, C., Seemann, O., Schummer, B., Steidler, A., Toktomambetova, L., et al. (1999). Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins. Urol. Res. 27, 157-163.
59. Stadler, W. M., Lerner, S. P., Groshen, S., Stein, J. P., Shi, S. R., Raghavan, D., et al. (2011). Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J. Clin. Oncol. 29, 3443-3449.
60. Sternberg, C. N., De Mulder, P., Schornagel, J. H., Theodore, C., Fossa, S. D., van Oosterom, A. T., et al. (2006). Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer 42, 50-54.
61. Tatokoro, M., Koga, F., Yoshida, S., Kawakami, S., Fujii, Y., Neckers, L., et al. (2012). Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. Int. J. Cancer 131, 987-996.
62. Tomlinson, D. C., Baldo, O., Harnden, P., and Knowles, M. A. (2007a). FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol. 213, 91-98.
63. Tomlinson, D. C., Hurst, C. D., and Knowles, M. A. (2007b). Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 26, 5889-5899.
64. Torti, D., Sassi, F., Galimi, F., Gastaldi, S., Perera, T., Comoglio, P. M., et al. (2012). A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. Int. J. Cancer 130, 1357-1366.
65. Torti, D., and Trusolino, L. (2011). Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol. Med. 3, 623-636.
66. Van den Broeck, A., Gremeaux, L., Topal, B., and Vankelecom, H. (2012). Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine. BMC Cancer 12:354. doi:10.1186/1471-2407-12-354
67. van Rhijn, B. W., Zuiverloon, T. C., Vis, A. N., Radvanyi, F., van Leenders, G. J., Ooms, B. C., et al. (2010). Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur. Urol. 58, 433-441.
68. von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., et al. (2000). Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 18, 3068-3077.
69. von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., et al. (2005). Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602-4608.
70. Weinstein, I. B. (2002). Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297, 63-64.
71. Williams, S. V., Hurst, C. D., and Knowles, M. A. (2013). Oncogenic FGFR3 gene fusions in bladder cancer. Hum. Mol. Genet. 22, 795-803.
72. Wong, F. Y., Liem, N., Xie, C., Yan, F. L., Wong, W. C., Wang, L., et al. (2012). Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with High BCL-2 expression. PLoS ONE 7:e50786. doi:10.1371/journal.pone.0050786
73. Yang, C. R., Ou, Y. C., Kuo, J. H., Kao, Y. L., Chen, C. L., Yean, S. Y., et al. (1997). Intracellular glutathione content of urothelial cancer in correlation to chemotherapy response. Cancer Lett. 119, 157-162.
74. Yu, H. M., and Wang, T. C. (2012). Mechanism of cisplatin resistance in human urothelial carcinoma cells. Food Chem. Toxicol. 50, 1226-1237.